DES (Diethylstilbestrol) Info

DES (Diethylstilbestrol) Info We welcome everyone from the DES community -- Mothers, Daughters, Sons, 3rd Generation and all exposed! In some clinics, it was given to every pregnant patient.

DES Info Association:

The DES tragedy of in-utero exposure and its devastating effects on multiple generations must not be forgotten. The medical community need education about the sequela of DES Exposure. (1) know how to screen the DES exposed, (2) Know the continueing long term effects of DES exposure, and (3) Provide prompt care when DES Exposed patients develop complications.

** What is DES (diethylstilbestrol)? **

DES (diethylstilbestrol), is a teratogenic and carcinogenic synthetic estrogen (Endocrine Disruptor) , is the world’s first major drug disaster. It was prescribed to millions of pregnant women for decades: from 1938 into the 1970s in the United States; and until the mid-1980s in parts of Latin America, Europe, Australia, and the Third World (Currently in Kenya). The currently proven effects of exposure include a rare vaginal cancer in DES Daughters; greater risk for breast cancer in DES Mothers; possible risk for testicular cancer in DES Sons, along with transgender and reproductive malformations; abnormal reproductive organs; infertility; high-risk pregnancies; Skeletal issues and an increased risk for breast cancer in DES Daughters. There are a number of other suspected effects, including auto-immune disorders, but many of these effects are still awaiting further research. For decades, Big Pharma claimed DES prevented miscarriages and problem pregnancies. It was sometimes given as an injection, but primarily it was prescribed in pill form. Never patented, DES was marketed under 200 different names, although the majority of the drug was actually produced by Eli Lilly. DES was sometimes even included in prescription prenatal vitamins. As early as 1938, studies showed that DES promoted cancer in lab animals. But at that time, people thought animal studies only provided a hint of what could happen in humans. Also, no one knew that drugs could cross the placenta and affect a baby in utero. (Note there was a 1941 mouse study that showed mice with absent or deformed fallopian tubes. The warning signs were there for humans.) In 1941, the original clinical uses for DES were to treat gonorrheal vaginitis, senile vaginitis, menopausal symptoms and to suppress lactation. Between 1941 and 1947, it was used for pregnancy without FDA approval. No controlled studies were ever conducted by the drug companies to determine the effectiveness or safety of DES for use during pregnancy, even after some scientists started questioning its efficacy in the 1950s. As early as 1953, research revealed that DES did not work (The Dieckmann Study) – that DES actually brought about higher rates of premature birth and infant mortality – yet DES continued to be prescribed to pregnant women for decades. This is because pharmaceutical companies continued to heavily promote DES use to doctors. The drug was a top moneymaker for Big Pharma. In the late 1960s, there was an unprecedented appearance of rare cancer in young women. Clear cell cancer (CCA) – a rare cancer of the vagina – was diagnosed in an age group never before found to develop it. (Normally elderly women developed CCA.) There were eight such cases at Massachusetts General Hospital in Boston alone. One of the mothers raised the question of whether her daughter's cancer might be connected to DES exposure in utero. Doctors discovered the DES link in 1971 and published their findings in the April 1971 issue of New England Journal of Medicine. News of the cancer cases made national headlines. However, the FDA did not act on this information until public pressure, including Congressional Hearings, forced the FDA to issue a warning about DES in November 1971. The drug was not banned for human use. DES was contraindicated for pregnancy by the FDA in 1972. It was not until September 2000 that the FDA finally withdrew its approval of DES for humans. Researchers are now investigating whether DES health issues are extending into the next generation, the so-called DES Grandchildren (Third Generation). As study results come in, there is growing evidence that this group has been adversely impacted by a drug prescribed to their grandmothers. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Nevertheless, they have paid millions in out-of-court settlements and verdicts to DES Daughters and Sons who suffered injuries from their exposure. Please join us in our mission to continue to provide information to the DES exposed on DES information and other health related information along with pushing for more physician education to know how to care for the DES exposed. Also, we are continuing to push for more research! Our moto is "Knowledge is Power" DES Info Association is a free resource for Diethylstilbestrol Information and Research

“DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE. The information on this site, including but not limited to text, graphics, images and other material, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you have any questions about how the information contained on this website may relate to you, you should seek the advice of a physician or other qualified health care professional.”

An Apology from the UK!
11/12/2025

An Apology from the UK!

Something's gone wrong and we've got some technical issues at our end. Please take a look at on Twitter for the most up-to-date information from us.

11/11/2025

DES Info: Excerpt from the DES Timeline.

■ “Testicular tumors, epididymal cysts, retained hypotrophic te**es and s***m abnormalities noted in DES Sons which a potential increased risk for developing carcinoma of the reproductive tract” (SOJ Urol. 1987 Dec;138(6):1446-50. (Newbold)

DES Info: DES = reproductive tract tumors. Proliferative lesions and reproductive tract tumors in male descendants of mi...
11/11/2025

DES Info: DES = reproductive tract tumors.

Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol.

Prenatal exposure to diethylstilbestrol (DES) is associated with reproductive tract abnormalities, subfertility and neoplasia in experimental animals and humans.

Studies using experimental animals suggest that the carcinogenic effects of DES may be transmitted to succeeding generations.

To further evaluate this possibility and to determine if there is a sensitive window of exposure, mice were treated with DES during three developmental stages: group 1 was treated on days 9-16 of gestation (2.5, 5 or 10 microg/kg maternal body weight) during major organogenesis; group II was treated once on day 18 of gestation (1000 microg/kg maternal body weight) just prior to birth; and group III was treated on days 1-5 of neonatal life (0.002 microg/pup/day).

In DES F(2) males there was an increased incidence of proliferative lesions of the rete te**is and tumors of the reproductive tract was observed.

Since these increases were seen in all DES treatment groups, all exposure periods were considered susceptible to perturbation by DES. These data suggest that, while fertility of the DES F(2) mice appeared unaltered, increased susceptibility for tumors is transmitted from the DES 'grandmothers' to subsequent generations.

Carcinogenesis. 2000 Jul;21(7):1355-63
Authors: Newbold RR, Hanson RB, Jefferson WN, Bullock BC, Haseman J, McLachlan JA.



DESInfo411@gmail.com

11/10/2025

DES Info: An excerpt from the DES Timeline.

■ “Diethylstilbestrol as a feed for slaughter cattle 1955” The Federal Pure Food and Drug Administration had recently approved the use of diethylstilbestrol in commercial cattle feeds. Stilbestrol has also been implanted experimentally in pellet or paste form under the skin of fattening animals and poultry. (Diethylstilbestrol As A Feed For Slaughter Cattle Paul Q. Guyer Asst. Extension Animal Husbandman https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=4259&context=extensionhist)

DES Info:  A DES Daughter shared her journey, heartache, and pain..I write this as a 70+year-old.  When my mother was pr...
11/10/2025

DES Info: A DES Daughter shared her journey, heartache, and pain..

I write this as a 70+year-old. When my mother was pregnant with me, she was prescribed the drug DES; diethylstilbestrol, to prevent miscarriage. My mother’s first pregnancy was uneventful. She subsequently had 2 miscarriages before she became pregnant with me.

DES is a synthetic estrogen. It was never properly tested. Pregnant women were given it without their consent at the Lying-In hospital in Boston by Dr. George Smith.

It was known in the 1940’s that DES caused cancer in mice. In 1947, despite this knowledge, DES began to be used in pregnant women. Dr. Smith thought miscarriage and preterm delivery were caused by a drop in estrogen. So, he thought giving women estrogen while pregnant was the solution. He declared that DES would “make a normal pregnancy more normal”.

On April 21, 1971, the Boston Globe reported that DES was the cause of a rare cancer, clear cell adenocarcinoma of the va**na, in 7 young women being treated for this disease at Massachusetts General Hospital. In 1971, I was 18 years old.

Upon learning what had happened, my mother arranged for me to see her gynecologist. It was my first visit to one. I asked if being DES exposed might affect my ability to have children. I was told if menstrual fluid could get out, s***m could get in.

I was, however, at increased risk of developing this rare cancer, which was treated with radical hysterectomy, and vaginectomy. Here began the countless gynecological visits I would have to have, including special procedures to evaluate the benign hallmarks of DES that lined my va**na and covered my cervix.

In 1975, I married. On November 11, 1976, I underwent emergency surgery for an about to rupture ectopic pregnancy. It was in my left Fallopian tube. As was the standard of care at that time, the tube was removed. It was a complete shock to learn that I was pregnant. I had had an odd period some weeks before that my doctor thought was relayed to ovulation. Back in the day, pregnancy tests were not run in those instances. I had just turned 23.

Our efforts to conceive again were met with failure. In desperation, I looked in the Yellow Pages, the “search engine” of the time, and made an appointment with a fertility specialist. G-d led me to the right person. He had recently read about a study done on DES daughters experiencing pregnancy loss. The study was done at Baylor University in Texas by Dr. Raymond Kaufman. He had done dye enhanced x-rays of the uterus in more than 70 women. All of them had uterine and/or fallopian tube abnormalities.

Not long after, I had this test. My uterus was deformed. The cavity was nearly nonexistent; what was there had the shape of the letter “Y”. I was advised that it was most likely impossible for me to have a successful pregnancy, to get some “help” to deal with it and decide what we as a couple wanted to do in terms of building a family. The doctor would also fully evaluate my fertility and help me try to conceive if I chose to do that. I was still 23 years old.

In 1978 I became pregnant again. I still have the temperature charts from those times. This was a twin pregnancy. I was told the likelihood was that I would not go full term, and to prepare for that. Shortly thereafter, the beta subunit test I was having weekly to track the pregnancy revealed that I was miscarrying. The year was 1978; I was 25.

My husband and I were also trying to adopt a baby at that time. The situation seemed so bleak, and I was a realist then, as I am now. Yes, we wanted to keep trying, but what we really needed was to have a family.

Adoption was very hard to do in those days. There were only a couple of listings in the Boston Yellow Pages. We learned that in Massachusetts, where we live, we could do an “Identified” adoption; that is, find a woman who is pregnant and wants to have her child adopted, and work with a lawyer. We found a young woman through a local Rabbi. We are Jewish. We called my father’s lawyer. The baby was born. It was a boy. We had 12 filled bottles in the refrigerator. I remember the dress I was wearing as we got ready to pick up our son. The phone rang. It was our lawyer. He had no idea we needed to work with a licensed adoption agency in the state. What we were doing was illegal. Instead of picking up our baby, we emptied the formula into the sink. While not a pregnancy loss, it was an enormous sadness.

I was plagued by depression in those days. Who wouldn’t be? At 23 we are barely beginning to live life as adults. We had been dealt an incredibly tough hand. I left my job. I became an activist in the DES movement, something I still do to this day. A friend and I run the page DES Info. We do not want to be forgotten.

In 1979, we identified another pregnant woman. She was 18. I was fully knowledgeable of the law at this point. On December 9, 1979, a baby boy was born. The biological father was in a motorcycle accident right after the birth, so the baby was placed in foster care, as he was unable to sign the paperwork. I lived in fear that something awful would happen. I could not imagine another loss of another baby. Of two adoptions not working out. Finally, 7 weeks later, we brought our son home. It was January 28th, 1980.

With a newborn at home, we weren’t trying to have a baby. Given my history of inability to conceive, we didn’t bother with birth control. I had a very hard time getting pregnant the second time. I found out I was pregnant again when our baby was only a few months old. By this time, I was working for an infertility specialist, a career that found me. I began experiencing pain and bleeding, as I had with my first ectopic pregnancy. I was hospitalized for observation. My boss was my doctor at that time. One of the top specialists in the city, I wanted to make sure, with only one fallopian tube left, that I had the best surgeon in case I ever needed one again. It was too soon to know if the pregnancy was in my deformed uterus, or my questionable Fallopian tube. On the evening of May 7,1980, having the same pain as I had with my first ectopic, I asked the doctor to do a laparoscopy. He agreed that it made sense at that point. My only thought was that my baby needed me. He was not yet legally ours according to the laws in the state. If I died, my husband would lose his wife, and his child. I requested that if my tube was the location of the pregnancy, to leave it closed. I had a deformed uterus that likely would not work anyway. I am a realist.

In the wee hours of May 8, my surgery began. The pregnancy was in my other Fallopian tube. The bleeding would not stop, and the bipolar cautery needed to stop it could not be located. My remaining Fallopian tube was removed.

Despite my request to have my tube sealed, I was shocked and devastated to learn that I would never become pregnant again. I was 26.

Tragedies change us permanently. We do go on, but I dare say we are different people than we would have been. My joy was found in raising our son. We have grandchildren now, and I love them more than anything in this world.

At the same time, I have never forgotten my losses, and how it felt going through them. I mourn to this day the loss of my ability to experience pregnancy. As a DES daughter who has been so active in this cause, I have known too many other exposed women who have had so many losses. Some because the cancer robbed them of their reproductive organs; so many who have had ectopic pregnancies; many more whose premature babies have suffered to this day with devastating problems related to being born too soon; and others whose babies did not survive.

We must never let the world forget – The DES Tragedy!


DESInfo411@gmail.com

DES Info: The role of DES in the development of the female reproductive tractYin Y, Lin C, Zhang I, Fisher AV, Dhandha M...
10/30/2025

DES Info: The role of DES in the development of the female reproductive tract

Yin Y, Lin C, Zhang I, Fisher AV, Dhandha M, Ma L. Homeodomain Transcription Factor Msx-2 Regulates Uterine Progenitor Cell Response to Diethylstilbestrol. J Stem Cell Transplant Biol. 2015;1(1):105. doi: 10.19104/jstb.2015.105. Epub 2015 May 12. PMID: 26457333; PMCID: PMC4596533.

This study findings speak to gene targets:
“We identified potential downstream targets of MSX-2, as well as genes whose regulation by DES is modulated through MSX-2. Discovery of these genes will lead to a better understanding of how DES, and possibly other endocrine disruptors, affects reproductive organ development.”

“Identification of these genes may shed light on how Msx2 regulate terminal differentiation of the uterus, and possibly other Msx2-expressing tissues.

For further information, please review the article or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

DES Info: Myeloid leukemia in an infant – Grandmother took DESChantrain, C.F., Sauvage, D., Brichard, B., Dupont, S., Po...
10/23/2025

DES Info: Myeloid leukemia in an infant – Grandmother took DES

Chantrain, C.F., Sauvage, D., Brichard, B., Dupont, S., Poirel, H.A., Ameye, G., De Weer, A., Vandenberghe, P., Detaille, T., Anslot, C., de Cléty, S.C. and Vermylen, C. (2009),

"Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero." Pediatr. Blood Cancer, 53: 220-222. https://doi.org/10.1002/pbc.22040

This report concludes with the following: “This case shows acute myeloid leukemia and the third pediatric leukemia reported after maternal diethylstilboestrol exposure.”

For further information, please review the article or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com



DESInfo411@gmail.com

DES Info: Insights into DES-sons’ abnormalities ..Jenny A. Visser, Anke McLuskey, Miriam Verhoef-Post, Piet Kramer, J. A...
10/21/2025

DES Info: Insights into DES-sons’ abnormalities ..

Jenny A. Visser, Anke McLuskey, Miriam Verhoef-Post, Piet Kramer, J. Anton Grootegoed, Axel P. N. Themmen, “Effect of Prenatal Exposure to Diethylstilbestrol on Müllerian Duct Development in Fetal Male Mice”

*This work was supported by The Netherlands Organization for Scientific Research (NWO) through GB-MW (Medical Sciences).
, Endocrinology, Volume 139, Issue 10, 1 October 1998, Pages 4244–4251, https://doi.org/10.1210/endo.139.10.6215

This study concludes with the following:
“Therefore, it is concluded that prenatal DES exposure of male mice delays the onset of Mullerian duct development, which may result in an asynchrony in the timing of Mullerian duct formation, with respect to the critical period of Mullerian duct regression, leading to persistence of Mullerian duct remnants in male mice.”

For further information, please review the article or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

Abstract. The clinical use of diethylstilbestrol (DES) by pregnant women has resulted in an increased incidence of ge***al carcinoma in the daughters born

Address

Dallas, TX

Telephone

+19728208400

Website

https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet,

Alerts

Be the first to know and let us send you an email when DES (Diethylstilbestrol) Info posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DES (Diethylstilbestrol) Info:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram